A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
ASSEMBLY BIOSCIENCES, INC.
ASMB
$284M
Mkt Cap
$25.55
+1.31%
ASSEMBLY BIOSCIENCES, INC. (ASMB) has a 5-year average return on invested capital (ROIC) of -90.3%. This is below average and may indicate limited pricing power.
ASSEMBLY BIOSCIENCES, INC. (ASMB) has a market capitalization of $406M. It is classified as a small-cap stock.
ASSEMBLY BIOSCIENCES, INC. (ASMB) does not currently pay a regular dividend.
ASSEMBLY BIOSCIENCES, INC. (ASMB) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
ASSEMBLY BIOSCIENCES, INC. (ASMB) reported annual revenue of $72 million in its most recent fiscal year, based on SEC EDGAR filings.
ASSEMBLY BIOSCIENCES, INC. (ASMB) has a net profit margin of -8.5%. The company is currently unprofitable.
ASSEMBLY BIOSCIENCES, INC. (ASMB) generated $-41 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
We are a biotechnology company developing innovative therapeutics targeting serious viral diseases with the potential to improve the lives of patients worldwide. Our pipeline includes multiple clinical-stage investigational therapies, including: (1) two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus (HDV) entry inhibitor; and (3) a highly potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Our pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is currently undergoing studies to enable a regulatory filing, and we have additional research programs against multiple antiviral targets.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 71M | 72M | 29M | - | - | - |
| Net Income | -6.4M | -6.1M | -40M | -61M | -93M | -130M |
| EPS | $-1.09 | $-0.55 | $-3.35 | $-160.56 | $-276.96 | $-36.00 |
| Free Cash Flow | -40M | -41M | -51M | 22M | -85M | -96M |
| ROIC | -4.5% | -5.1% | -107.9% | -149.0% | -112.6% | -76.9% |
| Gross Margin | - | 0.0% | - | - | - | - |
| Debt/Equity | 0.00 | 0.01 | 0.09 | 0.06 | 0.04 | 0.04 |
| Dividends/Share | $0.00 | $0.00 | - | - | - | - |
| Operating Income | -14M | -12M | -45M | -65M | -94M | -133M |
| Operating Margin | -19.1% | -16.8% | -159.3% | - | - | - |
| ROE | -3.2% | -5.1% | -107.9% | -149.0% | -112.6% | -76.9% |
| Shares Outstanding | 16M | 11M | 12M | 0M | 0M | 4M |
| Metric | 2014 | 2015 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 0 | 0 | 0 | N/A | N/A | N/A | 79M | N/A | N/A | N/A | 29M | 72M | 71M |
| Gross Margin | 0.0% | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | N/A |
| R&D | 11M | 18M | 33M | 44M | 73M | 86M | 107M | 69M | 70M | 49M | 56M | 65M | 65M |
| SG&A | 13M | 11M | 12M | 17M | 35M | 33M | 37M | 29M | 24M | 23M | 18M | 20M | 20M |
| EBIT | -24M | -30M | -45M | -52M | -93M | -103M | -65M | -133M | -94M | -65M | -45M | -12M | -14M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | -81.9% | N/A | N/A | N/A | -159.3% | -16.8% | -19.1% |
| Net Income | -24M | -28M | -44M | -43M | -91M | -98M | -62M | -130M | -93M | -61M | -40M | -6.1M | -6.4M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | -78.6% | N/A | N/A | N/A | -140.9% | -8.5% | -9.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 5.7M | 14M | 14M | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | -40.6% | -24.0% | -55.4% | -37.8% | -43.1% | -35.7% | -25.8% | -76.9% | -112.6% | -149.0% | -107.9% | -5.1% | -4.5% |
| ROE | -57.3% | -32.1% | -55.4% | -37.8% | -43.1% | -35.7% | -25.8% | -76.9% | -112.6% | -149.0% | -107.9% | -5.1% | -3.2% |
| ROA | -48.4% | -27.8% | -45.1% | -25.3% | -33.9% | -28.7% | -21.9% | -68.0% | -91.5% | -44.7% | -31.4% | -3.2% | -2.7% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -15M | -19M | -35M | 1.9M | -65M | -84M | -63M | -93M | -84M | 23M | -51M | -41M | -40M |
| Free Cash Flow | -15M | -19M | -35M | 995K | -65M | -86M | -63M | -96M | -85M | 22M | -51M | -41M | -40M |
| Owner Earnings | -26M | -27M | -40M | -7.0M | -94M | -105M | -86M | -99M | -92M | 17M | -54M | -46M | -45M |
| CapEx | 150K | 58K | 146K | 865K | 340K | 1.6M | 470K | 3.1M | 102K | 255K | 28K | 66K | 85K |
| Maint. CapEx | 50K | 114K | 80K | 219K | 643K | 494K | 691K | 466K | 498K | 450K | 129K | 129K | 122K |
| Growth CapEx | 100K | 0 | 66K | 646K | 0 | 1.1M | 0 | 2.6M | 0 | 0 | 0 | 0 | 0 |
| D&A | 50K | 114K | 80K | 219K | 643K | 494K | 691K | 466K | 498K | 450K | 129K | 129K | 122K |
| CapEx/OCF | N/A | N/A | N/A | 46.5% | N/A | N/A | N/A | N/A | N/A | 1.1% | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 11M | 7.9M | 5.0M | 8.6M | 28M | 21M | 22M | 5.2M | 6.6M | 5.1M | 3.1M | 4.7M | 5.1M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | -262M | -206M | -140M | -88M | -128M | -109M | -304M | -258M |
| Cash & Equiv. | 29M | 27M | 29M | 82M | 41M | 47M | 59M | 46M | 52M | 20M | 38M | 58M | 258M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.22 | 0.13 | 0.23 | 0.50 | 0.27 | 0.04 | 0.04 | 0.04 | 0.04 | 0.06 | 0.09 | 0.01 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0 | 0.0 |
| Equity | 59M | 119M | 80M | 113M | 211M | 273M | 241M | 169M | 83M | 41M | 33M | 207M | 199M |
| Total Assets | 71M | 134M | 98M | 169M | 268M | 340M | 283M | 191M | 102M | 137M | 119M | 258M | 236M |
| Total Liabilities | 13M | 15M | 18M | 56M | 57M | 67M | 43M | 22M | 19M | 96M | 86M | 51M | 37M |
| Intangibles | 42M | 42M | 29M | 29M | 29M | 29M | 29M | N/A | N/A | N/A | N/A | 0 | 0 |
| Retained Earnings | -136M | -164M | -208M | -251M | -342M | -439M | -502M | -631M | -725M | -786M | -826M | -832M | -841M |
| Working Capital | 28M | 65M | 46M | 110M | 204M | 258M | 200M | 138M | 81M | 95M | 68M | 206M | 198M |
| Current Assets | 29M | 68M | 54M | 123M | 223M | 283M | 224M | 154M | 97M | 134M | 116M | 255M | 233M |
| Current Liabilities | 1.1M | 3.4M | 7.1M | 13M | 18M | 24M | 24M | 16M | 16M | 39M | 48M | 49M | 35M |
| Per Share Data | |||||||||||||
| EPS | -204.00 | -108.60 | -30.84 | -28.92 | -47.76 | -44.64 | -21.00 | -36.00 | -276.96 | -160.56 | -3.35 | -0.55 | -1.09 |
| Owner EPS | -220.06 | -101.86 | -27.86 | -4.70 | -49.52 | -48.06 | -28.89 | -27.47 | -272.38 | 45.04 | -4.53 | -4.12 | -2.83 |
| Book Value | 502.28 | 453.20 | 55.66 | 76.42 | 110.86 | 124.92 | 81.29 | 46.83 | 245.94 | 107.77 | 2.78 | 18.57 | 12.50 |
| Cash Flow/Share | -128.40 | -71.36 | -24.30 | 1.26 | -34.19 | -38.44 | -21.27 | -25.89 | -251.29 | 59.64 | -4.26 | -3.69 | -0.39 |
| Dividends/Share | 0.00 | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 | 0.00 |
| Shares Out. | 0.1M | 0.3M | 1.4M | 1.5M | 1.9M | 2.2M | 3.0M | 3.6M | 0.3M | 0.4M | 12.0M | 11.1M | 15.9M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -23.5 |
| P/FCF | N/A | N/A | N/A | 784.1 | N/A | N/A | N/A | N/A | N/A | 0.2 | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | 6.9 | 2.4 | 2.0 | 0.9 | 0.6 | 0.7 | 1.1 | 2.7 | N/A | 2.0 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | 7.7 | N/A | N/A | N/A | 3.0 | N/A | 5.7 |
| FCF Yield | N/A | N/A | N/A | 0.1% | -12.9% | -15.6% | -29.7% | -98.6% | -142.0% | 50.6% | -56.2% | N/A | -9.8% |
| Market Cap | 0 | 0 | 0 | 780M | 504M | 550M | 213M | 98M | 60M | 44M | 91M | 0 | 406M |
| Avg. Price | 0.00 | 0.00 | 0.00 | 318.82 | 476.97 | 194.18 | 205.92 | 48.03 | 21.59 | 12.71 | 14.31 | 0.00 | 25.55 |
| Year-End Price | 0.00 | 0.00 | 0.00 | 527.04 | 265.44 | 251.28 | 72.12 | 27.12 | 14.76 | 9.72 | 15.16 | 0.00 | 25.55 |
ASSEMBLY BIOSCIENCES, INC. passes 1 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is +29.3%.
ASSEMBLY BIOSCIENCES, INC. (ASMB) has a debt-to-equity ratio of 0.01. This indicates a conservatively financed balance sheet.
ASSEMBLY BIOSCIENCES, INC. (ASMB) reported earnings per share (EPS) of $-0.55 in its most recent fiscal year.
ASSEMBLY BIOSCIENCES, INC. (ASMB) has a return on equity (ROE) of -5.1%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 13 years of financial data for ASSEMBLY BIOSCIENCES, INC. (ASMB), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ASSEMBLY BIOSCIENCES, INC. (ASMB) has a book value per share of $18.57, based on its most recent annual SEC filing.